Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptifibatide injection vs tirofiban in PCI for acute coronary syndrome
CTR20132880Phase 2Active
- Sponsor
- Nanjing Chang'ao Pharmaceutical Technology
- Start
- Feb 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of eptifibatide in acute coronary syndrome (ACS), sponsored by Nanjing Chang'ao Pharmaceutical Technology. Started Feb 2014; status: active.
02
Drugs
eptifibatide
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on CTR20132880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132880.